An Unusual Nodular Glomerular Lesion
A 67-year-old white male with chronic kidney disease (CKD) stage 3a (baseline Cr 1.5mg/dl) and type 2 diabetes mellitus for over 20 years, as well as hypertension and obesity presented for evaluation of left heel ulcerative wound that had been…
(HealthDay News) — Patients who regularly use proton pump inhibitors (PPIs) may be at increased risk of developing chronic kidney disease, according to research published online in the Journal of the American Society of Nephrology.
The new study findings are based on medical records from 173,321 Veterans Affairs patients who were prescribed a PPI and 20,270 other patients prescribed a histamine H2-receptor antagonist (H2-blocker).
Over 5 years, 15% of PPI users were diagnosed with chronic kidney disease, versus 11% of those on H2-blockers. After the researchers weighed other factors, PPI users still had a 28% greater risk. Few study patients — less than 0.2% — developed end-stage kidney failure. But the odds were almost doubled among PPI users.
Continue Reading
“I think people see these medications at the drug store and assume they’re completely safe,” Ziyad Al-Aly, MD, a kidney specialist with the Veterans Affairs St. Louis Health Care System, told HealthDay. “But there’s growing evidence they’re not as safe as we’ve thought.” And, Al-Aly said, the risk increased the longer people used the medications: Patients on PPIs for 1 to 2 years had a 3-fold higher risk of kidney failure than those who used the drugs for a month or less.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.